{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["198(1)"],"submitter":["Wu WC"],"funding":["Melissa Lee Cancer Foundation and Dr. Morris Chang"],"pubmed_abstract":["Purpose
Trastuzumab, a potent anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody, is conditionally reimbursed by the Taiwan National Health Insurance (NHI) for HER2-positive breast cancer (BC). Trastuzumab-induced cardiotoxicity studies have well characterized heart failure (HF) but fewer addressed arrhythmia, particularly the association of potential life threatening atrial fibrillation (Af) is poorly characterized. We aimed to study the trastuzumab-related risk of Af and HF using the claimed data of Taiwan NHI.Methods
A nationwide retrospective cohort of patients with BC from the Taiwan NHI reimbursement database from January 2007 to December 2016 was analyzed. Propensity score matching and competing risk model analysis were used for adjusting confou"],"journal":["Breast cancer research and treatment"],"pagination":["113-122"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9883308"],"repository":["biostudies-literature"],"pubmed_title":["The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: a population-based propensity score matching and competing risk model analysis."],"pmcid":["PMC9883308"],"pubmed_authors":["Wu WC","Huang CC","Lin YS","Liu CY","Feng CJ","Tseng LM","Chen YJ","Tsai YF","Lai JI","Chao TC"],"additional_accession":[]},"is_claimable":false,"name":"The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: a population-based propensity score matching and competing risk model analysis.","description":"Purpose
Trastuzumab, a potent anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody, is conditionally reimbursed by the Taiwan National Health Insurance (NHI) for HER2-positive breast cancer (BC). Trastuzumab-induced cardiotoxicity studies have well characterized heart failure (HF) but fewer addressed arrhythmia, particularly the association of potential life threatening atrial fibrillation (Af) is poorly characterized. We aimed to study the trastuzumab-related risk of Af and HF using the claimed data of Taiwan NHI.Methods
A nationwide retrospective cohort of patients with BC from the Taiwan NHI reimbursement database from January 2007 to December 2016 was analyzed. Propensity score matching and competing risk model analysis were used for adjusting confou","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-26T13:15:56.233Z","creation":"2024-11-06T15:32:21.089Z"},"accession":"S-EPMC9883308","cross_references":{"pubmed":["36586037"],"doi":["10.1007/s10549-022-06753-7"]}}